The consensus guideline states, "It is reasonable to use T-Wave Alternans for improving the diagnosis and risk stratification of patients with ventricular arrhythmias or who are at risk for developing life-threatening ventricular arrhythmias. (Level of Evidence: A)."

Commenting on the new guideline, David A. Chazanovitz, President and CEO of Cambridge Heart, Inc., the developer of the Microvolt T-Wave Alternans test stated, "This new societal guideline validates the importance of our diagnostic test. It provides assurance to the cardiology community of the efficacy of the test and the role it can play in managing patients at risk of sudden cardiac death. It serves to answer the concern of practicing cardiologists with respect to integrating the Alternans test into their practices as the societies have formally given guidance on MTWA testing for the first time. The guideline also provides new and important information for those insurance companies that are not yet reimbursing MTWA testing, and should aid in our efforts to achieve universal reimbursement for MTWA testing.

A joint press release issued yesterday by the three cardiology societies stated that the purpose of the document is to update and combine the previously published recommendations into one source approved by the major cardiology organizations in the United States and Europe. The Executive Summary can be found on all three websites and can be accessed on the ACC website using the following link www.acc.org/qualityandscience/clinical/pdfs/VASCDExecSum.FINAL.8.1 4.06.pdf. (Due to the length of this URL, it may be necessary to copy and paste it into your Internet browser's URL address field.) The full text of the document will be posted on the websites of the American College of Cardiology (www.acc.org), the American Heart Association (www.americanheart.org) and the European Society of Cardiology (www.escardio.org) early next month.

About Cambridge Heart

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the first diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the OTCBB under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com

About the Cambridge Heart Microvolt T-Wave Alternans Test

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heart rate is possible. The preparation for the test consists of placing proprietary sensors on a patient's chest. Extensive clinical research has shown that patients with symptoms of or, who are at risk of, life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk.

Statements contained in this press release about anticipated revenue growth, and all other statements that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates", "could" and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include customer delays in making final buying decisions, decreased demand for our products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology, failure to obtain or maintain adequate levels of third-party reimbursement for use of our products and other factors identified in our most recent Annual Report on Form 10-K under "Factors Which May Affect Future Results", which is on file with the SEC. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.

SOURCE: Cambridge Heart, Inc.

At Cambridge Heart, Inc.
Roderick de Greef, 781-271-1200 x231
Chief Financial Officer
roderickd@cambridgeheart.com
or
At Consulting for Strategic Growth
Stanley Wunderlich, 800-625-2236
info@csfg1.com